NU 2058: Potent CDK Inhibitor for Pharmaceutical Advancements
Discover NU 2058 (CAS: 161058-83-9), a critical guanidine-based compound for cell cycle research. As a leading supplier, we offer high-purity NU 2058 to support your oncology drug discovery and development needs. Request a quote and sample today.
Get a Quote & SampleHigh-Purity NU 2058: Essential for Cancer Research
NU 2058
As a trusted manufacturer and supplier of pharmaceutical intermediates in China, we offer NU 2058 with guaranteed purity of 97%+. This compound is vital for researchers investigating cell cycle regulation and developing novel cancer therapies. Our commitment to quality ensures reliable supply for your critical projects.
- Investigate Cell Cycle Regulation: Explore the role of NU 2058 as a potent inhibitor of CDK1 and CDK2 (IC50s = 7.0 and 17 μM), crucial for understanding cancer cell proliferation.
- Key Pharmaceutical Intermediate: Utilize NU 2058 as a precursor for advanced compounds like NU 6140, enhancing therapeutic specificity in drug development.
- Support for Oncology Research: Procure high-quality NU 2058 from a reliable supplier for your in vitro studies on human tumor cells and cancer treatment strategies.
- Competitive Pricing and Bulk Orders: Benefit from our advantageous pricing for bulk purchases of NU 2058, ensuring cost-effectiveness for your R&D budget.
Advantages of Sourcing NU 2058
Guaranteed Purity and Quality
Our NU 2058 is sourced from reputable manufacturers, ensuring a minimum purity of 97%+, critical for reproducible research outcomes. We are a trusted supplier committed to quality assurance.
Reliable Supply Chain
As a leading pharmaceutical intermediate supplier, we maintain a robust inventory of NU 2058 to meet your ongoing research and development needs. Secure your supply with us, your dependable manufacturer.
Expert Technical Support
Leverage our expertise in pharmaceutical intermediates. We provide essential technical data and support to assist you in effectively utilizing NU 2058 for your specific applications, from synthesis to research.
Key Applications of NU 2058
Cancer Therapeutics Research
NU 2058's potent CDK inhibition makes it invaluable for researching targeted cancer therapies, aiding in cell cycle arrest and apoptosis studies for various tumor types.
Pharmaceutical Intermediate Synthesis
Serve as a crucial building block in the synthesis of more complex pharmaceutical agents, such as NU 6140, enhancing selectivity for therapeutic targets.
Cell Biology Studies
Facilitate in-depth investigations into cell proliferation, DNA replication, and cell cycle checkpoints, providing insights into cellular mechanisms in both healthy and diseased states.
Drug Discovery and Development
Essential for early-stage drug discovery, offering researchers a reliable tool to screen and validate potential therapeutic targets within the cyclin-dependent kinase family.